Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research.
The share prose rose after the company had announced that Fluidigm mass cytometry technology and the Maxpar Direct Immune Profiling Assay are being utilized in a prospective observational cohort surveillance study of up to 2,000 adult participants hospitalized with COVID-19. — finance.yahoo.com/news/multi-study-covid-19-patients-123010989.html
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $5,86; stop-loss — $5,41.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Bought in at 3.50 and 5.50. Latest news has analyst thinking $12 target. Application is in for Emergency Use Authorization for covid saliva test that takes only 2 hours for results and uses 1000x less reagents. Also partnered with Department of Defense which if you read the articles, military has twice the infection rate as general public (tight quarters). All bullish if you ask me.